
Pre-made Abelacimab benchmark antibody ( Whole mAb, anti-F11/F11 mRNA therapeutic antibody, Anti-FXI/PTA Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-002
Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abelacimab (previously known as MAA 868) is a fully human, factor XI monoclonal antibody, being developed by Anthos Therapeutics under the license from Novartis, for the prevention of cardiovascular disorders including stroke due to thrombosis and thromboembolism in patients with atrial fibrillation.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-002-1mg | 1mg | 3090 | ||
GMP-Bios-ab-002-10mg | 10mg | 21890 | ||
GMP-Bios-ab-002-100mg | 100mg | 148000 | ||
GMP-Bios-ab-002-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody |
INN Name | Abelacimab |
Target | F11 mRNA |
Format | Whole mAb |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Lambda |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | 6r8x:CB |
Year Proposed | 2018 |
Year Recommended | 2019 |
Companies | Novartis |
Conditions Approved | na |
Conditions Active | Venous Thromboembolism; Stroke;Thrombosis |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
